The development of effective therapeutic agents to treat cases of CML exhibiting resistance to existing BCR-ABL inhibitors, such as imatinib, is an important issue that cannot be overlooked. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.